{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T10:33:55Z","timestamp":1787567635635,"version":"build-2736575974"},"reference-count":77,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Glucagon-like peptide (GLP)-1 receptor agonists (GLP-1RAs) (including medications that contain GLP-1 and other RAs), hereafter referred to as GLP-1 medicines, have significantly advanced the management of metabolic disease and weight management. Obesity is highly prevalent among cancer survivors at the time of diagnosis, and cancer treatments are associated with subsequent changes in weight, either gain or loss. Research has shown that obesity can adversely affect cancer treatment outcomes and survivorship, leading researchers to investigate the potential integration of GLP-1 medicines into oncology care. There is growing interest in understanding the effects of GLP-1 medicines on weight loss and cancer-related outcomes among individuals with obesity who are taking anticancer therapies, as well as individuals treated for cancer in the past who are long-term survivors. This review examines the literature to characterize what is known about GLP-1 medicine use among cancer survivors. The current literature, though limited and largely retrospective, suggests that GLP-1 medicines may contribute to weight loss among cancer survivors, with outcomes varying by cancer stage and type of anticancer therapy. It is important for healthcare providers to consider the potential negative impact of these GLP-1 medications on their patients, especially those with cancer cachexia or sarcopenic obesity, as well as those undergoing anticancer treatments that often lead to weight loss. While there is preclinical evidence suggesting that there are weight-loss independent effects that may be beneficial to individuals with cancer, use of GLP-1 medicines in patients of normal weight for reasons other than treatment of type 2 diabetes should be initiated with caution. On the positive side, these agents may help mitigate therapy-related toxicities, such as cardiotoxicity, with the potential to enhance survivorship outcomes. Unfortunately, there is a notable lack of well-designed randomized controlled trials evaluating the effects of GLP-1 medicines on weight loss, clinical endpoints, and cancer-related outcomes. Advancing the field requires a focus on elucidating the interactions between GLP-1 medicines and anticancer therapies, particularly their impact on treatment efficacy, nutritional status, and overall patient outcomes, both during treatment and in the long term.<\/jats:p>","DOI":"10.3390\/cancers18162714","type":"journal-article","created":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T09:31:59Z","timestamp":1787304719000},"page":"2714","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["GLP-1 Receptor Agonist Use in Cancer Survivors\u2014Challenges and Opportunities: A Narrative Review"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4802-9289","authenticated-orcid":false,"given":"Tanya","family":"Agurs-Collins","sequence":"first","affiliation":[{"name":"Division of Cancer Control and Population Sciences, National Cancer Institute, National Institutes of Health, 9609 Medical Center Drive, Rockville, MD 20850, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward R.","family":"Sauter","sequence":"additional","affiliation":[{"name":"Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, 9609 Medical Center Drive, Rockville, MD 20850, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,21]]},"reference":[{"key":"ref_1","unstructured":"National Cancer Institute (NCI) (2023). Cancer Survivors and Weight."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1200\/JCO.2016.66.4391","article-title":"Trends in Obesity Prevalence in Adults with a History of Cancer: Results from the US National Health Interview Survey, 1997 to 2014","volume":"34","author":"Greenlee","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e213520","DOI":"10.1001\/jamanetworkopen.2021.3520","article-title":"Association of Obesity with Survival Outcomes in Patients with Cancer: A Systematic Review and Meta-analysis","volume":"4","author":"Petrelli","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s11912-016-0539-4","article-title":"The obesity paradox in cancer: A review","volume":"18","author":"Lennon","year":"2016","journal-title":"Curr. Oncol. Rep."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1002\/osp4.606","article-title":"A systematic review of obesity as a barrier to accessing cancer screening services","volume":"8","author":"Graham","year":"2022","journal-title":"Obes. Sci. Pract."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e2532402","DOI":"10.1001\/jamanetworkopen.2025.32402","article-title":"Obesity Severity and Cancer Screening in US Adults","volume":"8","author":"Corpodean","year":"2025","journal-title":"JAMA Netw. Open"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Wang, Q., Li, Z., Wang, X.H., Li, B., Wang, C., and Xiang, Y. (2025). Effect of obesity on perioperative outcomes following lung cancer surgery: A systematic review and meta-analysis. Front. Oncol., 15.","DOI":"10.3389\/fonc.2025.1600503"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.33425\/2833-0307.1016","article-title":"The impact of obesity on acute skin toxicity from radiation treatment for breast cancer: Opportunities to predict and address","volume":"3","author":"Lombardo","year":"2024","journal-title":"Endocrinol. Metab. Nutr."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"154e","DOI":"10.1097\/PRS.0000000000000268","article-title":"Lymphedema and obesity: Is there a link?","volume":"134","author":"Mehrara","year":"2014","journal-title":"Plast. Reconstr. Surg."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1001\/jamaoncol.2025.2681","article-title":"GLP-1 Receptor Agonists and Cancer Risk in Adults with Obesity","volume":"11","author":"Dai","year":"2025","journal-title":"JAMA Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e2421305","DOI":"10.1001\/jamanetworkopen.2024.21305","article-title":"Glucagon-like peptide 1 receptor agonists and 13 obesity-associated cancers in patients with type 2 diabetes","volume":"7","author":"Wang","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1523\/JNEUROSCI.2714-16.2016","article-title":"Excitatory Hindbrain-Forebrain Communication Is Required for Cisplatin-Induced Anorexia and Weight Loss","volume":"37","author":"Alhadeff","year":"2017","journal-title":"J. Neurosci."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e13817","DOI":"10.1002\/jcsm.13817","article-title":"Cisplatin-Induced Muscle Wasting and Atrophy: Molecular Mechanism and Potential Therapeutic Interventions","volume":"16","author":"Huang","year":"2025","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1158\/1055-9965.EPI-12-0306","article-title":"Weight change and survival after breast cancer in the after breast cancer pooling project","volume":"21","author":"Caan","year":"2012","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_15","first-page":"230","article-title":"American Cancer Society nutrition and physical activity guideline for cancer survivors","volume":"72","author":"Rock","year":"2022","journal-title":"CA Cancer J. Clin."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"272","DOI":"10.5306\/wjco.v5.i3.272","article-title":"Weight gain following breast cancer diagnosis: Implication and proposed mechanisms","volume":"5","author":"Braun","year":"2014","journal-title":"World J. Clin. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"4203","DOI":"10.1200\/JCO.2016.68.4480","article-title":"Obesity and Breast Cancer Prognosis: Evidence, Challenges, and Opportunities","volume":"34","author":"Jiralerspong","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1056\/NEJMoa2416394","article-title":"Tirzepatide as Compared with Semaglutide for the Treatment of Obesity","volume":"393","author":"Aronne","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e261272","DOI":"10.1001\/jamanetworkopen.2026.1272","article-title":"Glucagon-Like Peptide-1 Receptor Agonist Switching and Treatment Persistence in Adults Without Diabetes","volume":"9","author":"Xie","year":"2026","journal-title":"JAMA Netw. Open"},{"key":"ref_20","unstructured":"Terhune, C. (2025). New Data Show Most Patients Now Stay on Wegovy, Zepbound After a Year, Reuters."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/oby.70137","article-title":"Reduced-Frequency GLP1 Therapy Maintains Weight, Body Composition, and Metabolic Syndrome Improvements: A Case Series","volume":"34","author":"Wong","year":"2026","journal-title":"Obesity"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e194751","DOI":"10.1172\/JCI194751","article-title":"Antiinflammatory actions of glucagon-like peptide-1-based therapies beyond metabolic benefits","volume":"135","author":"Wong","year":"2025","journal-title":"J. Clin. Investig."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Bednarz, K., Kowalczyk, K., Cwynar, M., Czapla, D., Czarkowski, W., Kmita, D., Nowak, A., and Madej, P. (2022). The Role of Glp-1 Receptor Agonists in Insulin Resistance with Concomitant Obesity Treatment in Polycystic Ovary Syndrome. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23084334"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"156004","DOI":"10.1016\/j.metabol.2024.156004","article-title":"Metabolic dysfunction-associated steatotic liver disease and its link to cancer","volume":"160","author":"Kalligeros","year":"2024","journal-title":"Metabolism"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13046-024-03263-w","article-title":"The GLP-1R agonist semaglutide reshapes pancreatic cancer associated fibroblasts reducing collagen proline hydroxylation and favoring T lymphocyte infiltration","volume":"44","author":"Cencioni","year":"2025","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s44324-025-00054-5","article-title":"Incretin triple agonist retatrutide (LY3437943) alleviates obesity-associated cancer progression","volume":"3","author":"Marathe","year":"2025","journal-title":"npj Metab. Health Dis."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e86","DOI":"10.1002\/lci2.86","article-title":"The beneficial hepatic effects of glucagon-like peptid 1 receptor agonists in patients with diabetes and metabolic dysfunction-associated steatotic liver disease are independent of weight loss","volume":"5","author":"Forlano","year":"2024","journal-title":"Liver Int. Commun."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"15151","DOI":"10.1038\/s41598-025-99790-3","article-title":"Association between the systemic inflammation response index and mortality in cancer survivors based on NHANES 2001-2018","volume":"15","author":"Yang","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1080\/0284186X.2023.2197124","article-title":"Insulin resistance in patients with cancer: A systematic review and meta-analysis","volume":"62","author":"Marmol","year":"2023","journal-title":"Acta Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s13046-024-02960-w","article-title":"T-cell infiltration and its regulatory mechanisms in cancers: Insights at single-cell resolution","volume":"43","author":"Yang","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"117668","DOI":"10.1016\/j.biopha.2024.117668","article-title":"Semaglutide decelerates the growth and progression of breast cancer by enhancing the acquired antitumor immunity","volume":"181","author":"Stanisavljevic","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1210\/clinem\/dgaf053","article-title":"Semaglutide Reprograms Macrophages via the GLP-1R\/PPARG\/ACSL1 Pathway to Suppress Papillary Thyroid Carcinoma Growth","volume":"110","author":"Wang","year":"2025","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ygyno.2024.10.004","article-title":"Tirzepatide as an innovative treatment strategy in a pre-clinical model of obesity-driven endometrial cancer","volume":"191","author":"Kong","year":"2024","journal-title":"Gynecol. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e250185","DOI":"10.1530\/ERC-25-0185","article-title":"GLP1 receptor agonism alters growth and therapeutic response in prostate cancer","volume":"32","author":"Bera","year":"2025","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s40264-023-01392-3","article-title":"Drug-Drug Interactions Between Glucagon-Like Peptide 1 Receptor Agonists and Oral Medications: A Systematic Review","volume":"47","author":"Calvarysky","year":"2024","journal-title":"Drug Saf."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1111\/dom.12291","article-title":"Activation of glucagon-like peptide-1 receptor inhibits tumourigenicity and metastasis of human pancreatic cancer cells via PI3K\/Akt pathway","volume":"16","author":"Zhao","year":"2014","journal-title":"Diabetes Obes. Metab."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1530\/EC-17-0294","article-title":"Exenatide modulates tumor-endothelial cell interactions in human ovarian cancer cells","volume":"6","author":"Kosowska","year":"2017","journal-title":"Endocr. Connect."},{"key":"ref_38","first-page":"e38379","article-title":"Tirzepatide: A Promising Drug for Type 2 Diabetes and Beyond","volume":"15","author":"Dutta","year":"2023","journal-title":"Cureus"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1186\/s12933-022-01585-7","article-title":"Impact of semaglutide on high-sensitivity C-reactive protein: Exploratory patient-level analyses of SUSTAIN and PIONEER randomized clinical trials","volume":"21","author":"Mosenzon","year":"2022","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_40","first-page":"294","article-title":"GLP-1 Receptor Agonist Use and Weight Change in Patients with Breast Cancer","volume":"39","author":"Shen","year":"2025","journal-title":"Oncology"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1158\/2767-9764.CRC-25-0554","article-title":"Weight Loss Patterns and Clinical Outcomes of GLP1 Receptor Agonists in Breast Cancer Survivors","volume":"6","author":"Sukumar","year":"2026","journal-title":"Cancer Res. Commun."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1200\/JCO.2026.44.2_suppl.83","article-title":"Real-world outcomes comparing the use of GLP-1 agonists in patiens with colon cancer and comorbid obesity: A propensity score matched analysis from Global Federated health Research Network","volume":"44","author":"Arya","year":"2026","journal-title":"J. Clin. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1080\/07357907.2025.2585512","article-title":"The Influence of GLP-1 Receptor Agonists on Five-Year Mortality in Colon Cancer Patients","volume":"43","author":"Cuomo","year":"2025","journal-title":"Cancer Investig."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"101734","DOI":"10.1016\/j.diabet.2026.101734","article-title":"Association between glucagon-like peptide-1 receptor agonists and colorectal cancer survival: A population-based cohort study","volume":"52","author":"Dosda","year":"2026","journal-title":"Diabetes Metab."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Fawzy, M.S., Alenezy, A., Jishu, J.A., Khan, I., Dessouky, A., Abdelmaksoud, A., Limbach, K.E., and Toraih, E.A. (2025). Survival Benefits of GLP-1 Receptor Agonists in Patients with Neuroendocrine Neoplasms: A Large-Scale Propensity-Matched Cohort Study. Cancers, 17.","DOI":"10.3390\/cancers17091593"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1210\/clinem\/dgaf703","article-title":"GLP-1 receptor agonists in patients with cancer are associated with reduced all-cause mortality and hospitalization","volume":"111","author":"Mahadevan","year":"2026","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ygyno.2025.06.012","article-title":"Association between glucagon-like peptide-1 receptor agonists and ovarian cancer survival: A population-based cohort study","volume":"199","author":"Wang","year":"2025","journal-title":"Gynecol. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: A systematic review and meta-analysis of randomised trials","volume":"9","author":"Sattar","year":"2021","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"115170","DOI":"10.1016\/j.ejca.2024.115170","article-title":"Glucagon-like Peptide-1 Agonists Reduce Cardiovascular Events in Cancer Patients on Immune Checkpoint Inhibitors","volume":"216","author":"Chiang","year":"2025","journal-title":"Eur. J. Cancer"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e70130","DOI":"10.1002\/phar.70130","article-title":"Real-World Cardiovascular Outcomes of GLP-1 Receptor Agonists in Women with Type 2 Diabetes and Breast Cancer","volume":"46","author":"Cornelio","year":"2026","journal-title":"Pharmacotherapy"},{"key":"ref_51","first-page":"83","article-title":"Glucagon-like peptide-1 receptor agonists in patients with anthracycline related cardiac dysfunction","volume":"11","author":"Scalia","year":"2025","journal-title":"Cardiooncology"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"e040919","DOI":"10.1161\/JAHA.125.040919","article-title":"Role of GLP-1 Receptor Agonists in Managing Cancer Therapy-Related Cardiac Dysfunction","volume":"14","author":"Vignarajah","year":"2025","journal-title":"J. Am. Heart Assoc."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"12027","DOI":"10.1200\/JCO.2025.43.16_suppl.12027","article-title":"Major adverse cardiovascular events (MACE) in cancer patients treated with tirzepatide compared to GLP-1 receptor agonists: A target trial emulation using real-world data","volume":"43","author":"Ashruf","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Wilbon, S.S., and Kolonin, M.G. (2023). GLP1 Receptor Agonists-Effects beyond Obesity and Diabetes. Cells, 13.","DOI":"10.3390\/cells13010065"},{"key":"ref_55","unstructured":"National Cancer Institute (NCI) (2026). What Is Cancer?."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1080\/17512433.2025.2606258","article-title":"Drug-drug interactions in targeted cancer therapies: A focus on tyrosine kinase inhibitors","volume":"18","author":"Stromatt","year":"2025","journal-title":"Expert. Rev. Clin. Pharmacol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1200\/JCO.22.01799","article-title":"Financial Toxicity in Cancer Care: Implications for Clinical Care and Potential Practice Solutions","volume":"41","author":"Khan","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2898","DOI":"10.1016\/j.clnu.2021.02.005","article-title":"ESPEN practical guideline: Clinical Nutrition in cancer","volume":"40","author":"Muscaritoli","year":"2021","journal-title":"Clin. Nutr."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","article-title":"Definition and classification of cancer cachexia: An international consensus","volume":"12","author":"Fearon","year":"2011","journal-title":"Lancet Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.ajcnut.2025.04.023","article-title":"Nutritional priorities to support GLP-1 therapy for obesity: A joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society","volume":"122","author":"Mozaffarian","year":"2025","journal-title":"Am. J. Clin. Nutr."},{"key":"ref_61","unstructured":"Cancer Research UK (2026). Cachexia (Wasting Syndrome), Cancer Research UK."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1016\/S0140-6736(26)00656-2","article-title":"Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): A multicentre, double-blind, randomised, placebo-controlled trial","volume":"407","author":"Horn","year":"2026","journal-title":"Lancet"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1038\/s41591-026-04386-7","article-title":"Orforglipron for maintenance of body weight reduction: The double-blind, randomized phase 3b ATTAIN-MAINTAIN trial","volume":"32","author":"Aronne","year":"2026","journal-title":"Nat. Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"79884","DOI":"10.18632\/oncotarget.20168","article-title":"Prevalence of malnutrition in patients at first medical oncology visit: The PreMiO study","volume":"8","author":"Muscaritoli","year":"2017","journal-title":"Oncotarget"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"e70070","DOI":"10.1111\/cob.70070","article-title":"Micronutrient and Nutritional Deficiencies Associated with GLP-1 Receptor Agonist Therapy: A Narrative Review","volume":"16","author":"Urbina","year":"2026","journal-title":"Clin. Obes."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Johnson, B., Milstead, M., Thomas, O., McGlasson, T., Green, L., Kreider, R., and Jones, R. (2025). Investigating nutrient intake during use of glucagon-like peptide-1 receptor agonist: A cross-sectional study. Front. Nutr., 12.","DOI":"10.3389\/fnut.2025.1566498"},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Silveira, E.A., da Silva Filho, R.R., Spexoto, M.C.B., Haghighatdoost, F., Sarrafzadegan, N., and de Oliveira, C. (2021). The Role of Sarcopenic Obesity in Cancer and Cardiovascular Disease: A Synthesis of the Evidence on Pathophysiological Aspects and Clinical Implications. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22094339"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1017\/S0029665115004279","article-title":"Sarcopenia and cachexia in the era of obesity: Clinical and nutritional impact","volume":"75","author":"Prado","year":"2016","journal-title":"Proc. Nutr. Soc."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"e2417115","DOI":"10.1001\/jamanetworkopen.2024.17115","article-title":"Sarcopenic Obesity and Outcomes for Patients with Cancer","volume":"7","author":"Liu","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"111624","DOI":"10.1016\/j.nut.2022.111624","article-title":"Sarcopenic obesity: What about in the cancer setting?","volume":"98","author":"Brasacchio","year":"2022","journal-title":"Nutrition"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1007\/s00198-025-07664-1","article-title":"Effects of Glucagon-Like Peptide-1 receptor agonists on bone health in people living with obesity","volume":"36","author":"Karam","year":"2025","journal-title":"Osteoporos. Int."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"731","DOI":"10.3904\/kjim.2023.386","article-title":"Cancer treatment-induced bone loss","volume":"39","author":"Choi","year":"2024","journal-title":"Korean J. Intern. Med."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"e240231","DOI":"10.1530\/JOE-24-0231","article-title":"The effects of GIP, GLP-1 and GLP-2 on markers of bone turnover: A review of the gut-bone axis","volume":"265","author":"Longo","year":"2025","journal-title":"J. Endocrinol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"s204","DOI":"10.1136\/bmj.s204","article-title":"GLP-1 drugs: New warning after rise in reported deaths from pancreatitis","volume":"392","author":"Baraniuk","year":"2026","journal-title":"BMJ"},{"key":"ref_75","first-page":"351","article-title":"Nutrition support whilst on glucagon-like peptide-1 based therapy. Is it necessary?","volume":"28","author":"Chavez","year":"2025","journal-title":"Curr. Opin. Clin. Nutr. Metab. Care"},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Xande, J.G., and Del Giglio, A. (2025). GLP-1 Receptor Agonists in Breast Cancer: A New Frontier in Obesity and Prognosis Management. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26167744"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"4413","DOI":"10.1007\/s11357-024-01494-5","article-title":"Prognostic impact of glucagon-like peptide-1 receptor (GLP1R) expression on cancer survival and its implications for GLP-1R agonist therapy: An integrative analysis across multiple tumor types","volume":"47","author":"Ungvari","year":"2025","journal-title":"Geroscience"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/16\/2714\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T09:30:03Z","timestamp":1787563803000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/16\/2714"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,21]]},"references-count":77,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["cancers18162714"],"URL":"https:\/\/doi.org\/10.3390\/cancers18162714","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,21]]}}}